Bookmark
Forward
Explore Curated Studies Results
Explore Literature Results
Explore Clinical Trials Results
QuickView for responses interleukin- 2
Most Correlated Studies
- L1000 CMAP - Colorectal cancer HT29 cells treated with ligand perturbagens
- L1000 CMAP - Prostate carcinoma VCaP cells treated with ligand perturbagens
- L1000 CMAP - Adenocarcinoma of breast MCF7 cells treated with ligand perturbagens
- L1000 CMAP - Amelanotic malignant melanoma of skin A375 cells treated with ligand perturbagens
- L1000 CMAP - Lung cancer A549 cells treated with ligand perturbagens
Most Relevant Literature
- Antigenic and immunogenic properties of recombinant proteins consisting of two immunodominant Africa…
- A Protease Activatable Interleukin-2 Fusion Protein Engenders Antitumor Immune Responses by Interfer…
- The Role of High Dose Interleukin-2 in the Era of Targeted Therapy.
- Rare Genetic Variants of Large Effect Influence Risk of Type 1 Diabetes.
- When is it OK to Stop Anti-Programmed Death 1 Receptor (PD-1) Therapy in Metastatic Melanoma?
Most Relevant Clinical Trials
- Therapeutic HIV Vaccine and Interleukin-2 to Increase the Immune System's Response to HIV
- Safety of and Immune Response to an HIV Vaccine (VRC-HIVDNA009-00-VP) Administered With Interleukin-…
- Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma
- Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Le…
- Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer
